Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Low Fat, High Protein, High Carbohydrate Complete Enteral Nutritional Compositions for Treatment of Burn Patients, 2157 [2014-00287]

Download as PDF Federal Register / Vol. 79, No. 8 / Monday, January 13, 2014 / Notices The invention relates to methods, compositions and kits for use in protection against and/or treatment of chemical warfare nerve agent (CWNA) and/or organophosphate (OP) pesticide/ insecticide exposure. In particular, the present invention relates to methods, compositions and kits for treating, preventing, inhibiting or reducing a seizure, status epilepticus, neuropathogenesis, or a neuropathology caused by exposure to a CWNA or an OP pesticide/insecticide using (a) imidazenil, (b) a combination treatment comprising imidazenil and [+]Huperzine A, (c) a combination treatment comprising imidazenil and []-Huperzine A, or (d) a combination treatment comprising imidazenil, [+]Huperzine A and [-]-Huperzine A. SUPPLEMENTARY INFORMATION: Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2014–00286 Filed 1–10–14; 8:45 am] BILLING CODE 3710–08–P Brenda S. Bowen, Army Federal Register Liaison Officer. Brenda S. Bowen, Army Federal Register Liaison Officer. DEPARTMENT OF DEFENSE AGENCY: ACTION: Department of the Army, DoD. Notice. Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/ 851,599, entitled ‘‘Measurements of the Inhibition of Synaptic Activity (MISA) to Detect, Study and Evaluate All Active Botulinum Neurotoxin Serotypes,’’ filed on March 8, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention. SUMMARY: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. tkelley on DSK3SPTVN1PROD with NOTICES ADDRESSES: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. FOR FURTHER INFORMATION CONTACT: VerDate Mar<15>2010 16:40 Jan 10, 2014 Jkt 232001 BILLING CODE 3710–08–P Department of the Army BILLING CODE 3710–08–P Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Contact Pathway and Tissue Kallikrein Inhibitors Can Prevent/Reduce Leakage Caused by Hantavirus DEPARTMENT OF DEFENSE Department of the Army Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Low Fat, High Protein, High Carbohydrate Complete Enteral Nutritional Compositions for Treatment of Burn Patients Department of the Army, DoD. Notice. Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/ 733,938, entitled ‘‘Low Fat, High Protein, High Carbohydrate Complete Enteral Nutritional Compositions for Treatment of Burn Patients,’’ filed on December 6, 2012. The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates to low fat, high protein, high carbohydrate enteral nutritional formulations for use in providing the complete nutritional needs of subjects with severe burn, methods of providing nutritional support to burn patients using these formulations, and methods of making the same. These complete enteral nutritional formulations are polymeric, concentrated, and do not contain added arginine. In addition, these enteral nutritional formulations are SUMMARY: Notice of Availability for Exclusive, Non-Exclusive, or Partially-Exclusive Licensing of an Invention Concerning Measurements of the Inhibition of Synaptic Activity (MISA) To Detect, Study and Evaluate All Active Botulinum Neurotoxin Serotypes [FR Doc. 2014–00287 Filed 1–10–14; 8:45 am] [FR Doc. 2014–00283 Filed 1–10–14; 8:45 am] ACTION: Department of the Army homogeneous solutions that flow through tubing well. The invention relates to measurements of spontaneous or evoked electrical activity in networked populations of primary neurons or stem cell-derived neurons as a rapid, sensitive assay for the presence of functional botulinum neurotoxin (BoNT) in various matrices. SUPPLEMENTARY INFORMATION: AGENCY: DEPARTMENT OF DEFENSE 2157 PO 00000 Frm 00011 Fmt 4703 Sfmt 4703 Department of the Army, DoD. Notice. AGENCY: ACTION: Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/ 851,573, entitled ‘‘Contact Pathway and Tissue Kallikrein Inhibitors can Prevent/Reduce Leakage Caused by Hantavirus,’’ filed on March 15, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. SUMMARY: For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619–6664, both at telefax (301) 619–5034. SUPPLEMENTARY INFORMATION: The invention relates to treatment of vascular leakage symptoms infected with the Hantavirus using drugs that are already FDA approved. FOR FURTHER INFORMATION CONTACT: Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2014–00285 Filed 1–10–14; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE Defense Acquisition Regulations System [Docket Number DARS–2013–0038] Submission for OMB Review; Comment Request ACTION: E:\FR\FM\13JAN1.SGM Notice. 13JAN1

Agencies

[Federal Register Volume 79, Number 8 (Monday, January 13, 2014)]
[Notices]
[Page 2157]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-00287]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Notice of Availability for Exclusive, Non-Exclusive, or 
Partially-Exclusive Licensing of an Invention Concerning Low Fat, High 
Protein, High Carbohydrate Complete Enteral Nutritional Compositions 
for Treatment of Burn Patients

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Provisional Patent Application Serial No. 
61/733,938, entitled ``Low Fat, High Protein, High Carbohydrate 
Complete Enteral Nutritional Compositions for Treatment of Burn 
Patients,'' filed on December 6, 2012. The United States Government, as 
represented by the Secretary of the Army, has rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to low fat, high 
protein, high carbohydrate enteral nutritional formulations for use in 
providing the complete nutritional needs of subjects with severe burn, 
methods of providing nutritional support to burn patients using these 
formulations, and methods of making the same. These complete enteral 
nutritional formulations are polymeric, concentrated, and do not 
contain added arginine. In addition, these enteral nutritional 
formulations are homogeneous solutions that flow through tubing well.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2014-00287 Filed 1-10-14; 8:45 am]
BILLING CODE 3710-08-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.